All News

RheumNow Podcast square

"Ask Cush Anything" Returns (7.21.2023)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports and this week, takes on 5 cases/questions from "Ask Cush Anything"

Read Article
RheumNow Podcast square

Anti-Drug Antibodies with Biologics (7.14.2023)

Jack Cush, MD

Dr. Jack Cush Reviews the news and journal reports on CVA, TKA, PJP, ADA, and more!

Read Article
ChatGPT,computer,learning

ICYMI: ChatGPT - A Boon or Threat to Scientific Publication?

Jack Cush, MD

ChatGPT is a new, artificial intelligence chatbot that has dramatically changed the digital worlds of education, research, graphic design, statistics and more. While this AI driven platform has the untold potential in generating written content, there is considerable concern in assuring that human-generated content of research, education and publishing has veracity.

Read Article
inflammati.png

ICYMI: LAVLI - A New Autoinflammatory Disorder

Jack Cush, MD

NIH researchers have have described a novel autoinflammatory disorder called "Lyn kinase-associated vasculopathy and liver fibrosis" (LAVLI), based on a mutation in the LYN gene (that encodes the Lyn kinase protein). They discovered that increased Lyn kinase activity promotes systemic inflammation, by altering microvascular permeability and neutrophil recruitment, while at the same time promoting hepatic fibrosis.

Read Article
Bringing pivotal clinical trials to you: announcing RheumNow’s Poster Hall, featuring previously presented, sponsor-generated clinical trial posters designed to educate and inform. https://t.co/dHg0rrKcQ8 https://t.co/qtUxGg3waX

Links:

Dr. John Cush RheumNow ( View Tweet)
Watch: Zoster Management and Vaccination Drs. Janet Pope and Kevin Winthrop at EULAR 2023 in Milan, Italy. https://t.co/JcZNaeYuqh https://t.co/WF1PdlIbTO

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: ChatGPT - A Boon or Threat to Scientific Publication? https://t.co/nt4m6n27A3 https://t.co/oo88u5X86Z

Links:

Dr. John Cush RheumNow ( View Tweet)
Bringing pivotal clinical trials to you: announcing RheumNow’s Poster Hall, featuring previously presented, sponsor-generated clinical trial posters designed to educate and inform. https://t.co/CeLTCbB2nO https://t.co/qYXt8gCHjd

Links:

Dr. John Cush RheumNow ( View Tweet)
In Memoriam: Dr. K. Frank Austen (1928-2023) Rheumatology mourns the loss of a historic leader in the field, Dr. K. Frank Austen, who died at his home in Maine on June 23, 2023, at the age of 95. https://t.co/mtRQ8D5bWt https://t.co/fAQ9ebK95R

Links:

Dr. John Cush RheumNow ( View Tweet)
RT @Yuz6Yusof : #EULAR2023 #OP0143 Promising therapy. A Phase 2 RCT of Dazodalidep (CD40L-i) in #Sjogren showed significantly more patients on DAZ group met reduction in ESSDAI vs placebo. Interesting to see higher hurdle ESSDAI favored DAZ Group. Phase 3 RCTs are underway

Dr. John Cush RheumNow ( View Tweet)

#EULAR2023 #POS0112 Consistent with clinical response, Post-hoc analyses of Phase 2 RCT of Deucravacitinib (Tyk2-i) showed this therapy suppressed both IFN and B cell pathways - a broader mode of action in reducing #SLE pathophysiology. Look forward to Phase 3 results

Dr. John Cush RheumNow ( View Tweet)

RT @AurelieRheumo : The risk of osteoarticular infection following Staph aureus bacteremia is twice higher in RA (1/4) than non RA pop (1/8) Use of TNFi & orthopedic implants associated w/ OAI risk Mortality however similar in RA and non RA groups #EULAR23 POS0033

Dr. John Cush RheumNow ( View Tweet)

RT @bella_mehta : Obesity in #AOSD – predicted the development of a chronic disease course and biologic DMARD failure, 139 pts with AOSD- 19% Obese (BMI>30) observational study. abst#AB1503 #EULAR2023

Dr. John Cush RheumNow ( View Tweet)

RT @drdavidliew : Men trying to conceive were prev told to avoid MTX. Another myth busted Why? Spermatozoa lack the FPGS enzyme responsible for MTX-PG metabolism, the tiny amount of MTX-PG in sperm isn’t active. No quality issues! OP0224 #EULAR2023 https://t.co/i4WGmoWOwU)

Links:

Dr. John Cush RheumNow ( View Tweet)

RT @Yuz6Yusof : #EULAR2023 #POS1075 Which biologics have the lowest retention rate in Elderly patients (=>65 yrs) in Rheumatoid Arthritis? Data from Italian registry showed 1/3 discontinued biologics at 2 yrs. IL6-i: lowest persistence; Abatacept: highest

Dr. John Cush RheumNow ( View Tweet)

RT @Janetbirdope : #ClinicalPearl Rx of #scleroderma #ILD -add another drug. MMF, then Cyclo, Rituximab, ?tocilizumab; if progressive fibrosis then #Nintedanib ?Pirfenidone Small RCT of MMF v Tacrolimus - looked the same -helpful if MMF fails, future pregnancy OP0240 #EULAR2023

Dr. John Cush RheumNow ( View Tweet)

RT @Janetbirdope : A shame. Pts with #scleroderma are dying waiting for organ transplant- we should list and work them up for Tx earlier. PAH Pts May do worse @eular_org #EULAR2023 @RheumNow OP0241

Dr. John Cush RheumNow ( View Tweet)

RT @Yuz6Yusof : #EULAR2023 #POS1207 Promising therapy for dermatomyositis. Data from Stage One of Phase 2 RCT (N=18) showed Anti-IFN Beta mAb improved clinical, PROs, extra-muscular activity and reduced CK levels vs Placebo. No cases of HZV. One to watch out in the next few year

Dr. John Cush RheumNow ( View Tweet)

RT @Janetbirdope : #SLE #EULAR recommendations What is new - use LESS #glucocorticoids, aim for none or 5 mg/d or less, use #biologics early if needed to prevent damage, #lupus #nephritis consider less pulse dose if using, voclosporin vs Belimumab ? it depends #EULAR2023

Dr. John Cush RheumNow ( View Tweet)

RT @synovialjoints : Late Breaker - #EULAR2023 update on imaging of large vessel vasculitis. Ultrasound is now recommended as first line imaging test in all patients with suspected GCA, and axillary arteries should be in the standard examination, Dejaco C et al, Abst#LB0009

Dr. John Cush RheumNow ( View Tweet)

How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×